enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.

Company profile
Ticker
ENZ
Exchange
Website
CEO
Elazar Rabbani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Enzo Clinical Labs, Inc. • Enzo Life Sciences, Inc. • Enzo Therapeutics, Inc. • Enzo Realty LLC • Enzo Realty II, LLC ...
IRS number
132866202
ENZ stock data
Latest filings (excl ownership)
8-K
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
6 Sep 23
8-K/A
Financial Statements and Exhibits
28 Jul 23
8-K
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp
24 Jul 23
EFFECT
Notice of effectiveness
19 Jul 23
424B3
Prospectus supplement
18 Jul 23
S-3/A
Shelf registration (amended)
18 Jul 23
CORRESP
Correspondence with SEC
18 Jul 23
CORRESP
Correspondence with SEC
18 Jul 23
8-K
Other Events
17 Jul 23
UPLOAD
Letter from SEC
14 Jul 23
Transcripts
ENZ
Earnings call transcript
2023 Q1
13 Dec 22
ENZ
Earnings call transcript
2022 Q3
10 Jun 22
ENZ
Earnings call transcript
2022 Q2
15 Mar 22
ENZ
Earnings call transcript
2022 Q1
16 Dec 21
ENZ
Earnings call transcript
2021 Q4
12 Oct 21
ENZ
Earnings call transcript
2021 Q3
10 Jun 21
ENZ
Earnings call transcript
2021 Q2
16 Mar 21
ENZ
Earnings call transcript
2021 Q1
10 Dec 20
ENZ
Earnings call transcript
2020 Q4
13 Oct 20
ENZ
Earnings call transcript
2020 Q3
8 Jun 20
Latest ownership filings
SC 13G
1 MAIN CAPITAL MANAGEMENT, LLC
11 Sep 23
4
Kara Cannon
5 Sep 23
SC 13D/A
LABORATORY CORP OF AMERICA HOLDINGS
24 Jul 23
11-K
Annual report of employee stock purchases
29 Jun 23
4
Patricia Eckert
31 May 23
SC 13D/A
Radoff Bradley Louis
10 May 23
SC 13D
LABORATORY CORP OF AMERICA HOLDINGS
27 Mar 23
4
James G. Wolf
13 Feb 23
4
Ian B. Walters
13 Feb 23
4
MARY TAGLIAFERRI
13 Feb 23
Financial summary
Quarter (USD) | Apr 23 | Jan 23 | Oct 22 | Jul 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jul 22 | Jul 21 | Jul 20 | Jul 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.63 mm | 3.63 mm | 3.63 mm | 3.63 mm | 3.63 mm | 3.63 mm |
Cash burn (monthly) | 807.33 k | 2.37 mm | 5.22 mm | 3.97 mm | 1.68 mm | 2.42 mm |
Cash used (since last report) | 4.07 mm | 11.98 mm | 26.30 mm | 20.04 mm | 8.50 mm | 12.19 mm |
Cash remaining | -439.05 k | -8.34 mm | -22.67 mm | -16.41 mm | -4.86 mm | -8.56 mm |
Runway (months of cash) | -0.5 | -3.5 | -4.3 | -4.1 | -2.9 | -3.5 |
Institutional ownership, Q2 2023
58.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 51 |
Opened positions | 5 |
Closed positions | 10 |
Increased positions | 9 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 29.49 bn |
Total shares | 29.31 mm |
Total puts | 12.50 k |
Total calls | 60.20 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Harbert Fund Advisors | 5.18 mm | $9.52 bn |
Harbert Discovery Fund | 5.18 mm | $17.03 mm |
LH Laboratory Corp. Of America | 4.86 mm | $5.79 mm |
Renaissance Technologies | 2.70 mm | $4.98 mm |
Tang Capital Management | 2.30 mm | $4.23 bn |
Vanguard | 1.73 mm | $3.18 bn |
Dimensional Fund Advisors | 1.27 mm | $2.33 bn |
Potomac Capital Management | 1.05 mm | $1.93 bn |
BLK Blackrock | 998.48 k | $1.84 bn |
Fuller & Thaler Asset Management | 985.66 k | $1.81 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Aug 23 | Kara Cannon | Common Stock, $0.01 Par Value | Payment of exercise | Dispose F | No | No | 1.54 | 63,700 | 98.10 k | 296,480 |
31 Aug 23 | Kara Cannon | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 0 | 345,080 | 0.00 | 360,180 |
26 May 23 | Patricia Eckert | Stock Option (to acquire Common Stock) Common Stock | Grant | Acquire A | No | No | 2.29 | 25,000 | 57.25 k | 25,000 |
13 Feb 23 | Wolf James G. | Common Stock, $0.01 par value | Buy | Acquire P | Yes | No | 1.29 | 5,000 | 6.45 k | 115,000 |
13 Feb 23 | Wolf James G. | Common Stock, $0.01 par value | Buy | Acquire P | No | No | 1.285 | 5,000 | 6.43 k | 4,100,000 |
13 Feb 23 | Wolf James G. | Short Put Option (obligation to buy) Common Stock, $0.01 par value | Sell | Acquire S | No | No | 1.12 | 750 | 840.00 | 2,163 |
13 Feb 23 | Wolf James G. | Short Put Option (obligation to buy) Common Stock, $0.01 par value | Sell | Dispose S | No | No | 0.03 | 750 | 22.50 | 0 |
13 Feb 23 | Wolf James G. | Short Put Option (obligation to buy) Common Stock, $0.01 par value | Sell | Acquire S | No | No | 1.01 | 324 | 327.24 | 324 |
13 Feb 23 | Wolf James G. | Long Call Option Common Stock, $0.01 par value | Sell | Dispose S | No | No | 0.19 | 324 | 61.56 | 483 |
10 Feb 23 | Wolf James G. | Common Stock, $0.01 par value | Buy | Acquire P | No | No | 1.29 | 5,000 | 6.45 k | 4,095,000 |
News
Enzo Biochem Announces Departure Of Hamid Erfanian And Appointment Of Kara Cannon As Interim CEO, Effective September 5, 2023
6 Sep 23
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
25 Jul 23
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
25 Jul 23
Why Expion360 Holdings Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
25 Jul 23
12 Health Care Stocks Moving In Monday's After-Market Session
24 Jul 23